832 related articles for article (PubMed ID: 27775825)
1. Impact of type of calcineurin inhibitor on post-transplant tuberculosis: Single-center study from India.
Agarwal SK; Bhowmik D; Mahajan S; Bagchi S
Transpl Infect Dis; 2017 Feb; 19(1):. PubMed ID: 27775825
[TBL] [Abstract][Full Text] [Related]
2. Comparison of four different immunosuppression protocols without long-term steroid therapy in kidney recipients monitored by surveillance biopsy: five-year outcomes.
Anil Kumar MS; Irfan Saeed M; Ranganna K; Malat G; Sustento-Reodica N; Kumar AM; Meyers WC
Transpl Immunol; 2008 Nov; 20(1-2):32-42. PubMed ID: 18773960
[TBL] [Abstract][Full Text] [Related]
3. An open-label, randomized trial indicates that everolimus with tacrolimus or cyclosporine is comparable to standard immunosuppression in de novo kidney transplant patients.
Sommerer C; Suwelack B; Dragun D; Schenker P; Hauser IA; Witzke O; Hugo C; Kamar N; Merville P; Junge M; Thaiss F; Nashan B;
Kidney Int; 2019 Jul; 96(1):231-244. PubMed ID: 31027892
[TBL] [Abstract][Full Text] [Related]
4. Tacrolimus in pancreas transplantation: a multicenter analysis. Tacrolimus Pancreas Transplant Study Group.
Gruessner RW
Clin Transplant; 1997 Aug; 11(4):299-312. PubMed ID: 9267719
[TBL] [Abstract][Full Text] [Related]
5. Mycophenolate mofetil decreases rejection in simultaneous pancreas-kidney transplantation when combined with tacrolimus or cyclosporine.
Stegall MD; Simon M; Wachs ME; Chan L; Nolan C; Kam I
Transplantation; 1997 Dec; 64(12):1695-700. PubMed ID: 9422404
[TBL] [Abstract][Full Text] [Related]
6. Conversion from tacrolimus to cyclosporine in patients with new-onset diabetes after renal transplant: an open-label randomized prospective pilot study.
Rathi M; Rajkumar V; Rao N; Sharma A; Kumar S; Ramachandran R; Kumar V; Kohli HS; Gupta KL; Sakhuja V
Transplant Proc; 2015 May; 47(4):1158-61. PubMed ID: 26036543
[TBL] [Abstract][Full Text] [Related]
7. Impact of Tacrolimus Compared With Cyclosporin on the Incidence of Acute Allograft Rejection in Human Immunodeficiency Virus-Positive Kidney Transplant Recipients.
Gathogo E; Harber M; Bhagani S; Levy J; Jones R; Hilton R; Davies G; Post FA;
Transplantation; 2016 Apr; 100(4):871-8. PubMed ID: 26413990
[TBL] [Abstract][Full Text] [Related]
8. Immune monitoring with a lymphocyte adenosine triphosphate assay in kidney transplant recipients treated with a calcineurin inhibitor.
Sugiyama K; Tsukaguchi M; Toyama A; Satoh H; Saito K; Nakagawa Y; Takahashi K; Tanaka S; Onda K; Hirano T
Exp Clin Transplant; 2014 Jun; 12(3):195-9. PubMed ID: 24907718
[TBL] [Abstract][Full Text] [Related]
9. Randomized controlled study comparing reduced calcineurin inhibitors exposure versus standard cyclosporine-based immunosuppression.
Hernández D; Miquel R; Porrini E; Fernández A; González-Posada JM; Hortal L; Checa MD; Rodríguez A; García JJ; Rufino M; Torres A
Transplantation; 2007 Sep; 84(6):706-14. PubMed ID: 17893603
[TBL] [Abstract][Full Text] [Related]
10. Side effects and efficacy of renal sparing immunosuppression in pediatric liver transplantation-A single center matched cohort study.
Leiskau C; Rajanayagam J; Pfister ED; Goldschmidt I; Junge N; Karch A; Lerch C; Richter N; Lehner F; Schrem H; Baumann U
Pediatr Transplant; 2018 Aug; 22(5):e13207. PubMed ID: 29729061
[TBL] [Abstract][Full Text] [Related]
11. Calcineurin Inhibitor Nephrotoxicity Through the Lens of Longitudinal Histology: Comparison of Cyclosporine and Tacrolimus Eras.
Nankivell BJ; PʼNg CH; OʼConnell PJ; Chapman JR
Transplantation; 2016 Aug; 100(8):1723-31. PubMed ID: 27306529
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and safety of tacrolimus compared with cyclosporin A microemulsion in renal transplantation: 2 year follow-up results.
Krämer BK; Montagnino G; Del Castillo D; Margreiter R; Sperschneider H; Olbricht CJ; Krüger B; Ortuño J; Köhler H; Kunzendorf U; Stummvoll HK; Tabernero JM; Mühlbacher F; Rivero M; Arias M;
Nephrol Dial Transplant; 2005 May; 20(5):968-73. PubMed ID: 15741208
[TBL] [Abstract][Full Text] [Related]
13. Prednisone withdrawal 14 days after liver transplantation with mycophenolate: a prospective trial of cyclosporine and tacrolimus.
Stegall MD; Wachs ME; Everson G; Steinberg T; Bilir B; Shrestha R; Karrer F; Kam I
Transplantation; 1997 Dec; 64(12):1755-60. PubMed ID: 9422416
[TBL] [Abstract][Full Text] [Related]
14. Clinical outcome in heart transplant recipients receiving everolimus in combination with dosage reduction of the calcineurin inhibitor cyclosporine A or tacrolimus.
Fuchs U; Zittermann A; Ensminger SM; Schulz U; Gummert JF
Transpl Immunol; 2014 Aug; 31(2):87-91. PubMed ID: 24932812
[TBL] [Abstract][Full Text] [Related]
15. Conversion from tacrolimus-mycophenolate mofetil to tacrolimus-mTOR immunosuppression after kidney-pancreas transplantation reduces the incidence of both BK and CMV viremia.
Knight RJ; Graviss EA; Nguyen DT; Kuten SA; Patel SJ; Gaber L; Gaber AO
Clin Transplant; 2018 Jun; 32(6):e13265. PubMed ID: 29676018
[TBL] [Abstract][Full Text] [Related]
16. Cyclosporine A versus tacrolimus in combination with mycophenolate mofetil and steroids as primary immunosuppression after lung transplantation: one-year results of a 2-center prospective randomized trial.
Zuckermann A; Reichenspurner H; Birsan T; Treede H; Deviatko E; Reichart B; Klepetko W
J Thorac Cardiovasc Surg; 2003 Apr; 125(4):891-900. PubMed ID: 12698153
[TBL] [Abstract][Full Text] [Related]
17. Time-Dependent and Immunosuppressive Drug-Associated Adverse Event Profiles in De Novo Kidney Transplant Recipients Converted from Tacrolimus to Sirolimus Regimens.
Felix MJ; Felipe CR; Tedesco-Silva H; Osmar Medina-Pestana J
Pharmacotherapy; 2016 Feb; 36(2):152-65. PubMed ID: 26799522
[TBL] [Abstract][Full Text] [Related]
18. Cryptosporidium infection after renal transplantation in an endemic area.
Bhadauria D; Goel A; Kaul A; Sharma RK; Gupta A; Ruhela V; Gupta A; Vardhan H; Prasad N
Transpl Infect Dis; 2015 Feb; 17(1):48-55. PubMed ID: 25620388
[TBL] [Abstract][Full Text] [Related]
19. Association of immunosuppressive maintenance regimens with posttransplant lymphoproliferative disorder in kidney transplant recipients.
Sampaio MS; Cho YW; Shah T; Bunnapradist S; Hutchinson IV
Transplantation; 2012 Jan; 93(1):73-81. PubMed ID: 22129761
[TBL] [Abstract][Full Text] [Related]
20. Randomized trial of cyclosporine and tacrolimus therapy with steroid withdrawal in living-donor renal transplantation: 5-year follow-up.
Lee YJ; Kim B; Lee JE; Kim YG; Kim DJ; Kim SJ; Joh JW; Oh HY; Huh W
Transpl Int; 2010 Feb; 23(2):147-54. PubMed ID: 19744223
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
